Citation

  • Authors: Guerard, M., Robin, T., Perron, P., Hatat, A. S., David-Boudet, L., Vanwonterghem, L., Busser, B., Coll, J. L., Lantuejoul, S., Eymin, B., Hurbin, A., Gazzeri, S.
  • Year: 2018
  • Journal: Cancer Lett 420 146-155
  • Applications: in vitro / DNA, siRNA / jetPEI, jetPRIME
  • Cell types:
    1. Name: A549
      Description: Human lung carcinoma cells, type II pneumocytes
      Known as: A-549
    2. Name: H322
    3. Name: H358
      Description: Human bronchioalveolar carcinoma; non-small cell lung carcinoma cells
    4. Name: H441
      Description: Human lung papillary adenocarcinoma

Abstract

Many Receptor Tyrosine Kinases translocate from the cell surface to the nucleus in normal and pathological conditions, including cancer. Here we report the nuclear expression of insulin-like growth factor-1 receptor (IGF1R) in primary human lung tumours. Using lung cancer cell lines and lung tumour xenografts, we demonstrate that the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) gefitinib induces the nuclear accumulation of IGF1R in mucinous lung adenocarcinoma by a mechanism involving the intracellular re-localization of the growth factor amphiregulin. Amphiregulin allows the binding of IGF1R to importin-beta1 and promotes its nuclear transport. The nuclear accumulation of IGF1R by amphiregulin induces cell cycle arrest through p21(WAF1/CIP1) upregulation, and prevents the induction of apoptosis in response to gefitinib. These results identify amphiregulin as the first nuclear localization signal-containing protein that interacts with IGF1R and allows its nuclear translocation. Furthermore they indicate that nuclear expression of IGF1R contributes to EGFR-TKI resistance in lung cancer.

Go to